Vaccine effectiveness against onward transmission of SARS-CoV2-infection by variant of concern and time since vaccination, Belgian contact tracing, 2021.
Bayesian analysis
Contact Tracing
Covid19
Infection
Infectiousness
SARS-CoV2
Susceptibility
Transmission
Vaccine effectiveness
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
11 05 2022
11 05 2022
Historique:
received:
20
01
2022
revised:
04
04
2022
accepted:
05
04
2022
pubmed:
24
4
2022
medline:
6
5
2022
entrez:
23
4
2022
Statut:
ppublish
Résumé
During the first half of 2021, we observed high vaccine effectiveness (VE) against SARS-CoV2-infection. The replacement of the alpha-'variant of concern' (VOC) by the delta-VOC and uncertainty about the time course of immunity called for a re-assessment. We estimated VE against transmission of infection (VET) from Belgian contact tracing data for high-risk exposure contacts between 26/01/2021 and 14/12/2021 by susceptibility (VEs) and infectiousness of breakthrough cases (VEi) for a complete schedule of Ad26.COV2.S, ChAdOx1, BNT162b2, mRNA-1273 as well as infection-acquired and hybrid immunity. We used a multilevel Bayesian model and adjusted for personal characteristics (age, sex, household), background exposure, calendar week, VOC and time since immunity conferring-event. VET-estimates were higher for mRNA-vaccines, over 90%, compared to viral vector vaccines: 66% and 80% for Ad26COV2.S and ChAdOx1 respectively (Alpha, 0-50 days after vaccination). Delta was associated with a 40% increase in odds of transmission and a decrease of VEs (72-64%) and especially of VEi (71-46% for BNT162b2). Infection-acquired and hybrid immunity were less affected by Delta. Waning further reduced VET-estimates: from 81% to 63% for BNT162b2 (Delta, 150-200 days after vaccination). We observed lower initial VEi in the age group 65-84 years (32% vs 46% in the age group 45-64 years for BNT162b2) and faster waning. Hybrid immunity waned slower than vaccine-induced immunity. VEi and VEs-estimates, while remaining significant, were reduced by Delta and waned over time. We observed faster waning in the oldest age group. We should seek to improve vaccine-induced protection in older persons and those vaccinated with viral-vector vaccines.
Sections du résumé
BACKGROUND
During the first half of 2021, we observed high vaccine effectiveness (VE) against SARS-CoV2-infection. The replacement of the alpha-'variant of concern' (VOC) by the delta-VOC and uncertainty about the time course of immunity called for a re-assessment.
METHODS
We estimated VE against transmission of infection (VET) from Belgian contact tracing data for high-risk exposure contacts between 26/01/2021 and 14/12/2021 by susceptibility (VEs) and infectiousness of breakthrough cases (VEi) for a complete schedule of Ad26.COV2.S, ChAdOx1, BNT162b2, mRNA-1273 as well as infection-acquired and hybrid immunity. We used a multilevel Bayesian model and adjusted for personal characteristics (age, sex, household), background exposure, calendar week, VOC and time since immunity conferring-event.
FINDINGS
VET-estimates were higher for mRNA-vaccines, over 90%, compared to viral vector vaccines: 66% and 80% for Ad26COV2.S and ChAdOx1 respectively (Alpha, 0-50 days after vaccination). Delta was associated with a 40% increase in odds of transmission and a decrease of VEs (72-64%) and especially of VEi (71-46% for BNT162b2). Infection-acquired and hybrid immunity were less affected by Delta. Waning further reduced VET-estimates: from 81% to 63% for BNT162b2 (Delta, 150-200 days after vaccination). We observed lower initial VEi in the age group 65-84 years (32% vs 46% in the age group 45-64 years for BNT162b2) and faster waning. Hybrid immunity waned slower than vaccine-induced immunity.
INTERPRETATION
VEi and VEs-estimates, while remaining significant, were reduced by Delta and waned over time. We observed faster waning in the oldest age group. We should seek to improve vaccine-induced protection in older persons and those vaccinated with viral-vector vaccines.
Identifiants
pubmed: 35459558
pii: S0264-410X(22)00441-8
doi: 10.1016/j.vaccine.2022.04.025
pmc: PMC9001203
pii:
doi:
Substances chimiques
Ad26COVS1
JT2NS6183B
RNA, Viral
0
Vaccines
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3027-3037Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Science. 2021 Aug 13;373(6556):
pubmed: 34210892
Lancet. 2022 Mar 5;399(10328):924-944
pubmed: 35202601
Lancet Infect Dis. 2022 Feb;22(2):183-195
pubmed: 34756186
Euro Surveill. 2021 Nov;26(44):
pubmed: 34738514
J Infect Dis. 2022 Jun 1;225(11):1909-1914
pubmed: 34979030
Lancet Reg Health Eur. 2022 Jan;12:100252
pubmed: 34729548
N Engl J Med. 2021 Jul 1;385(1):90-92
pubmed: 33852796
BMJ. 2021 Nov 24;375:e067873
pubmed: 34819275
Science. 2022 Jan 14;375(6577):183-192
pubmed: 34855510
Lancet. 2022 Feb 26;399(10327):814-823
pubmed: 35131043
Lancet Infect Dis. 2022 Feb;22(2):e52-e58
pubmed: 34534512
Science. 2022 Jan 21;375(6578):331-336
pubmed: 34735261
Vaccine. 2021 Sep 15;39(39):5456-5460
pubmed: 34454789
N Engl J Med. 2022 Feb 24;386(8):744-756
pubmed: 34986294
N Engl J Med. 2021 Oct 28;385(18):1718-1720
pubmed: 34496200
N Engl J Med. 2022 Jan 27;386(4):340-350
pubmed: 35021002
Euro Surveill. 2021 Aug;26(31):
pubmed: 34355689
J Med Biochem. 2022 Apr 8;41(2):199-203
pubmed: 35510202
N Engl J Med. 2021 Dec 9;385(24):e85
pubmed: 34706170
N Engl J Med. 2021 Aug 19;385(8):759-760
pubmed: 34161702
Lancet. 2021 Dec 18;398(10318):2258-2276
pubmed: 34863358
Lancet. 2021 Oct 16;398(10309):1407-1416
pubmed: 34619098
Nat Commun. 2021 Dec 13;12(1):7251
pubmed: 34903718
Lancet Infect Dis. 2022 Jan;22(1):12-14
pubmed: 34762853
Nat Commun. 2021 Nov 4;12(1):6379
pubmed: 34737312
Science. 2022 Mar 11;375(6585):1151-1154
pubmed: 35084937
MMWR Morb Mortal Wkly Rep. 2021 Aug 13;70(32):1081-1083
pubmed: 34383732
N Engl J Med. 2022 Mar 31;386(13):1207-1220
pubmed: 35172051
Science. 2022 Jan 07;375(6576):43-50
pubmed: 34812653
PLoS Comput Biol. 2022 Mar 30;18(3):e1009965
pubmed: 35353810
N Engl J Med. 2021 Dec 23;385(26):2485-2487
pubmed: 34731553
JAMA Netw Open. 2021 Nov 1;4(11):e2132540
pubmed: 34726743
Lancet Microbe. 2022 Jan;3(1):e52-e61
pubmed: 34806056
Geroscience. 2022 Jun;44(3):1229-1240
pubmed: 35394604
Lancet Reg Health West Pac. 2021 Dec;17:100299
pubmed: 34746899